Syngene International Ltd

Syngene International Ltd has announced that its Board of Directors will convene on October 27, 2026, to consider and approve the un-audited standalone and consolidated financial results for the quarter and half-year ending September 30, 2026. The company has also closed its trading window for insiders from October 1, 2026, to October 29, 2026. An investor and analyst conference call is scheduled for October 28, 2026, with details to be provided on the company's website.

Syngene International Ltd has announced the closure of its trading window for dealing in the company's securities. This closure will be effective from October 1, 2026, and will remain in effect until 48 hours after the declaration of the un-audited financial results for the quarter and half-year ending September 30, 2026. This measure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct.

Syngene International Ltd has announced the cancellation of a scheduled meeting with institutional investor Bajaj AMC. The meeting was originally set to take place on Thursday, September 24, 2026. This cancellation is a follow-up to a previous intimation regarding the meeting. The company has also stated that this information will be made available on its official website, www.syngeneintl.com, for public record.

Syngene International Ltd announced the resignation of Mr. Pramuch Goel, Head Corporate Affairs & Communications and a member of the Executive Committee (Senior Management Personnel). His resignation is effective from the close of business hours on September 21, 2026. Mr. Goel is leaving to pursue other career opportunities. The company has provided details as required by SEBI Listing Regulations, including the reason for cessation and the effective date. The resignation is in line with regulatory requirements for disclosure of senior management changes.

Syngene International Ltd has communicated the remittance of its final dividend for the financial year 2025-26. The dividend, amounting to 12.50% or Rs 1.25 per equity share, was approved by shareholders at the Annual General Meeting held on July 29, 2026. The company has dispatched dividend warrants or initiated electronic transfers to shareholders who have not registered their email IDs but have provided their addresses. Shareholders can verify the credit and contact KFin Technologies Limited for any discrepancies. Further details are available on the company's website.

Syngene International Ltd has entered into a Share Subscription and Shareholders Agreement with Ampin C&I Power Twelve Private Limited for the acquisition of renewable power. The company will invest ₹2,52,00,000 to acquire 25,20,000 equity shares, representing 12.44% on an undiluted basis, with a minimum of 7.93% on a fully diluted basis post-investment by other entities. This strategic investment aims to enhance Syngene's renewable power consumption, support its decarbonization goals, reduce energy costs, and lower its carbon footprint. The acquisition does not involve related parties and aligns with Syngene's renewable energy objectives.

Syngene International Ltd announced the resignation of Mr. Kush Parmar from his position as Independent Director, effective July 29, 2026. Mr. Parmar will also step down from the Risk Management Committee and the Science and Technology Committee. The resignation is attributed to existing and increasing commitments in the USA, making it difficult to devote sufficient time to the company while residing outside India. The company expressed appreciation for his contributions. Mr. Parmar confirmed no other material reasons for his resignation.

Syngene International Ltd reported its Q1 FY27 results, with revenue from operations at ₹736 Cr, a 16% decrease year-on-year from ₹875 Cr in Q1 FY26. Operating EBITDA saw a significant drop of 56% to ₹91 Cr from ₹206 Cr. The company cited a lack of offtake from a major biologics client and forex hedge loss as primary reasons for the performance dip. Profit After Tax (PAT) before exceptional items was ₹11 Cr, down 99% from ₹87 Cr. The company announced strategic shifts with Kiran Mazumdar-Shaw taking on the role of Executive Chairperson and Siddharth Mittal as the new MD & CEO. They aim to focus on CDMO and AI-led services for sustainable growth. The company also announced board changes with Dr. Vijaya Chandru and Dr. Arun Chandavarkar appointed as Independent Directors, while Dr. Kush Parmar steps down. Syngene also signed an MoU with THSTI for clinical development and translational research.

Syngene International Ltd announced its un-audited financial results for the quarter ended June 30, 2026. The Board of Directors approved the standalone and consolidated financial results as per Indian Accounting Standards (Ind-AS). The results were presented following a board meeting held on July 29, 2026. Key financial metrics such as revenue, expenses, profit before tax, and earnings per share for the quarter are detailed in the filing, along with comparative figures from the previous year and preceding quarter. The company also provided information on its paid-up equity share capital and reserves.

Syngene International Ltd announced the outcome of its Board Meeting held on July 29, 2026. The Board approved the un-audited financial results (standalone and consolidated) for the quarter ended June 30, 2026, prepared as per Indian Accounting Standards (Ind-AS). The results, along with the Limited Review Reports, have been submitted. The meeting commenced at 10:00 am IST and concluded at 03:31 pm IST. The company also informed that the financial results will be available on its website.